Shenzhen Zhongge Biotechnology Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agent coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via linkers acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorders, transplant rejection, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome.
Korean pharmaceutical stocks rose across the board May 13, a day after U.S. President Donald Trump signed off on the most favored nation executive order, a drug pricing policy expected to benefit biosimilar makers in the U.S., according to Celltrion Inc.
Hitgen Ltd. has prepared and tested interleukin-17 receptor A (IL17RA; CD217) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections, asthma, multiple sclerosis, psoriasis, rheumatoid arthritis and inflammatory disorders.
Researchers from Trinity College Dublin, Princeton University and collaborators have discovered that blocking the uptake of lipids by immune cells within the ascites microenvironment could reshape treatment for advanced ovarian cancer.
Kymera Therapeutics Inc. has announced a new oral IRF5 degrader program with potential to treat immuno-inflammatory diseases, such as lupus, Sjögren’s syndrome, rheumatoid arthritis and inflammatory bowel disease.
Immunity is not a function most people particularly associate with the liver. But because of its connection to the gut, the liver is exposed to bacterial metabolites as few other organs are. And when either the liver or the gut is not functioning well, it can adversely affect immunity as well. The liver is connected to the gut via both the biliary system and the portal vein. Those two conduits allow metabolites from the gut microbiome to influence what’s going on in the liver. Both liver and gut damage can affect this communication for the worse. And surprisingly, one of the consequences is immune dysfunction.
Planting seed money and “wishing” is not enough to claim “irreparable harm” to secure a preliminary injunction or to establish the standing required to appeal a patent board decision, the U.S. Court of Appeals for the Federal Circuit ruled May 7 in two decisions involving Incyte Corp. and Sun Pharmaceutical Industries Ltd.
Ahead Therapeutics SL has received positive feedback from the EMA on its way toward initiating regulatory toxicology studies for its lead program in myasthenia gravis. The feedback supports the company’s scientific approach.
RSS
